Oncologic outcomes and prognostic impact of urothelial recurrences in patients undergoing segmental and total ureterectomy for upper tract urothelial carcinoma by Pedrosa, Jose A. et al.
CUAJ • March-April 2015 • Volume 9, Issues 3-4
© 2015 Canadian Urological Association
E187
Original research
Cite as: Can Urol Assoc J 2015;9(3-4):E187-92. http://dx.doi.org/10.5489/cuaj.2408
Published online April 13, 2015.
Abstract
Introduction: We evaluated the impact of urothelial recurrences 
in a cohort of patients undergoing segmental (SU) and total ure-
terectomy (TU) as an alternative to nephroureterectomy (NU) 
for upper tract urothelial carcinoma.
Methods: Between 1999 and 2012, patients who underwent SU, 
TU and NU for treatment of upper tract urothelial carcinoma were 
evaluated. Demographic, surgical, pathologic and oncologic data 
were collected. Recurrence-free (RFS) and disease-specific survival 
(DSS) were analyzed using Kaplan-Meier and multivariable Cox 
methods.
Results: A total 141 patients were evaluated, 35 underwent SU, 
10 TU and 96 NU. Patients who underwent TU were more likely 
to have bilateral disease (p < 0.01), solitary kidney (p < 0.01), and 
multifocal disease (p = 0.01). Organ-confined (p < 0.01) and low-
grade disease (p < 0.01) were more common in the TU and SU 
groups compared with NU. At a median follow-up of 56.9 months 
(range: 0.2–181.1) disease relapse occurred in 88 (55.3%) patients. 
Localized recurrence occurred in 31.1% of SU/TU group compared 
to 27.1% (p = 0.62) of the NU group. Neither total nor segmen-
tal ureterectomy demonstrated significantly worse RFS (p = 0.26 
and p = 0.81), CSS (p = 0.96 and p = 0.52) or overall survival 
(p = 0.59 and p = 0.55) compared with complete NU. Localized 
urothelial recurrence did not confer increased risk of cancer-specific 
(p = 0.73) or overall mortality (p = 0.39). The paper’s most important 
limitations include its retrospective nature and its relatively small 
number of patients.  
Conclusion: No significant survival differences were demonstrated 
between surgical approaches for upper tract urothelial cancer. 
Localized urothelial recurrence after surgical treatment for upper 
tract urothelial cancer does not affect mortality in this population. 
TU with ileal-substitution may provide an alternative option for 
patients with extensive ureteral disease and poor renal function. 
Introduction 
Isolated urothelial tumours of the ureter account for 30% 
of upper tract urothelial carcinoma, representing a small 
fraction of this already rare disease.1,2 Traditionally, surgery 
for upper tract urothelial carcinoma consists of nephroure-
terectomy (NU), including resection of bladder cuff, with 
or without regional retroperitoneal and/or pelvic lymphad-
enectomy. The removal of the entire ipsilateral urinary tract 
for upper tract urothelial carcinoma was supported by data 
demonstrating a high incidence of multifocal tumours and 
rates of ipsilateral recurrence in this disease population.3
Encouraged by the non-cancer related survival benefits of 
nephron-sparing surgery,4 a conservative surgical approach 
for upper tract urothelial carcinoma has been evaluated. 
Potential benefits of ureteral resection for the upper tract 
urothelial carcinoma population may be even more critical 
due to the inherent incidence of chronic kidney disease 
following surgery and the potential need for postoperative 
chemotherapy.5 Alternatives to NU include endoscopic 
tumour resections/ablations, segmental ureterectomy (SU), 
or total ureterectomy (TU) with urinary tract reconstruction. 
The potential benefits of renal preservation must be weighed 
against the potential impact of localized urothelial recur-
rences, which may or may not affect the overall course of 
the disease. We compared the recurrence patterns of patients 
undergoing NU and SU/TU for upper tract urothelial carci-
noma and evaluated survival in these groups.
Methods 
We evaluated patients who underwent surgical treatment 
for upper tract urothelial carcinoma, including NU, SU and 
TU, between January 1999 and August 2012. Resection was 
performed that included the ureter distal to the tumour and 
bladder cuff in all cases. Patients with metastatic disease at 
Jose A. Pedrosa, MD; Timothy A. Masterson, MD; Kevin R. Rice, MD; Hristos Z. Kaimakliotis, MD;  
M. Francesca Monn, MD; Richard Bihrle, MD; Michael O. Koch, MD; Ronald S. Boris, MD
Department of Urology, Indiana University School of Medicine, Indianapolis, IN
Oncologic outcomes and prognostic impact of urothelial recurrences 
in patients undergoing segmental and total ureterectomy for 
upper tract urothelial carcinoma
Original research
CUAJ • March-April 2015 • Volume 9, Issues 3-4E188
Pedrosa et al.
presentation or history of muscle invasive bladder cancer 
were excluded from the study. TU was performed as previ-
ously described by Armatys and colleagues6 and indicated 
for patients with multifocal ureteral disease and solitary kid-
ney or extensive bilateral disease where segmental resection 
would not be feasible. Patients with locally advanced dis-
ease, defined by disease extending outside the ureter, were 
not considered amenable to TU. Regional retroperitoneal 
and/or pelvic lymph node dissection was performed based 
on clinical suspicion for lymph node involvement and/or 
surgeon’s preference.
We retrospectively reviewed data from medical records. 
For purpose of the analysis, patients evaluated before 2004 
were assigned as low grade if they were grade 1 (1973 WHO 
classification) and as high grade if they were grade 2 or 3. 
The study endpoints were recurrence-free survival (RFS), 
cancer-specific survival (CSS), and overall survival (OS). For 
survival analysis, patients currently alive were censored at 
the data of last follow-up. Recurrence was defined by radio-
graphic, endoscopic, or histologic documentation of local 
failure or distant metastasis. Localized urothelial recurrence 
was used for patients who presented with recurrent disease 
arising from the urothelium, including bladder, ipsilateral 
upper urinary tract, and contralateral urinary tract. 
Pearson’s chi-squared and Mann Whitney tests were used 
to compare categorical and continuous variables, respective-
ly. The Kaplan-Meier method with log rank tests was used to 
compare survival between groups. Cox proportional hazards 
regression was used to evaluate variables associated with 
overall and cancer-specific mortality. Any variables found 
in univariable analysis with p < 0.05 were included in a 
multivariable cox proportional hazards model. All statistical 
analyses were performed using SPSS (SPSS Inc., Chicago, IL) 
and a priori p values less than 0.05 were considered sig-
nificant for statistical tests and analysis. Institutional Review 
Board approval was granted for the conduct of the study.
Results 
A total of 141 patients were identified, including 96 who 
underwent NU and 45 patients who underwent ureteral 
resection (35 SU and 10 TU with ileal ureter creation) 
(Table 1). Patients who underwent TU were more likely to 
have bilateral disease (p < 0.01), solitary kidney (p < 0.01), 
and multifocal disease (p = 0.01). Organ-confined disease 
(p < 0.01) and low-grade disease (p < 0.01) were more 
common in the TU and SU groups than NU.
Table 1. Clinicopathologic characteristic of patients according to the type of surgery
Variables Type of surgery p value
Median age (range) 72 (41–88) 69 (43–84) 71 (43–95) 0.52
Gender Male 8 (80.0) 23(65.7) 58 (60.4) 0.44
 Female 2 (20.0) 12 (34.3) 38 (39.6)
Race Caucasian 8 (80.0) 34 (97.1) 91 (94.8) 0.11
 Non-caucasian 2 (20.0) 1 (2.9) 5 (5.2)
Median CCI (range) 3 (2–7) 3 (2–7) 3 (3-8) 0.56
Median creatinine mg/dL 1.3 (0.5–3.4) 1.2 (0.5–3.4) 1.4 (0.7–2.8) 0.47
History of NMIBC 6 (60.0) 38 (39.9) 11 (31.4) 0.25
Side Right 6 (60.0) 14 (40.0) 54 (56.2) <0.01
 Left 2 (20.0) 21 (60.0) 42 (43.8)
 Bilateral 2 (20.0) 0 (0) 0 (0)
Solitary kidney 6 (60.0) 2 (5.7) 2 (2.1) <0.01
pT stage pTis/pTa/pT0 6(60.0) 18 (51.4) 24 (25) <0.01
 pT1 3 (30.0) 2 (5.7) 24 (25)
pT2 1(10.0) 7 (20.0) 13 (13.5)
pT3 0 (0.0) 7 (20.0) 25 (26.0)
pN stage pNx/pN0 9(90.0) 33 (94.3) 79 (82.3) 0.2
 pN+ 1 (10.0) 2 (5.7) 17 (17.7)
Grade Low 2 (20.0) 16 (45.7) 15 (15.6) <0.01
 High 8 (80.0) 19 (54.3) 81 (84.4)
Multifocal 4 (40.0) 2 (5.7) 10 (10.4) 0.01
LVI 1 (10) 5 (14.3) 24 (25.0) 0.27
CIS 3 (30.0) 8 (22.9) 26 (27.1) 0.85
CCI: Charlson Comorbidity Index; NMIBC: non-muscle invasive bladder cancer; LVI: lymphovascular invasion; CIS, carcinoma in situ; SU, segmental ureterectomy; TU: total ureterectomy; SU: 
segmental ureterectomy; NU: nephroureterectomy.
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Recurrence analysis 
At a median follow-up of 56.9 months (range: 0.2–181.1), 
68 (42.8%) patients were alive without disease, 4 (2.5%) 
were alive with disease, 41 (25.8%) were dead of disease 
and 28 (17.6%) were dead from other causes. A total of 71 
(50.3%) patients relapsed during the follow-up period. Initial 
recurrence sites included bladder in 33 (23.4%) patients, 
contralateral upper tract in 2 (1.4%), ipsilateral upper tract 
in 5 (3.5%), and distant metastasis in 31 (22.0%). Ipsilateral 
recurrences represented 11.1% of the recurrences in the SU/
TU group (Fig. 1). 
Recurrence in the remaining urothelium occurred in 
31.1% of the patients in the SU/TU groups compared to 
27.1% in the NU group, however this was not significant 
(p = 0.62). Pathologic information was available for 35 
(87.5%) patients. Stage distribution of urothelial recurrences 
was as follows: 28 (80%) patients had pT1/pTa/pTis dis-
ease and 7 (20.0%) patients relapsed with pT2 or higher. 
Low- and high-grade disease recurrence was demonstrated 
in 7 (20%) and 28 (80%), respectively. Additionally, when 
looking at ipsilateral upper tract recurrences identified in the 
SU group, we found that 3 out of a total of 5 recurrences 
occurred at the renal pelvis away from the initial resection 
site. 
Survival analysis 
When compared to the NU group, neither TU nor SU signifi-
cantly affected RFS (p = 0.26 and p = 0.81), CSS (p = 0.96 
and p = 0.52) or OS (p = 0.59 and p = 0.55). Actuarial 3-year 
RFS was 48.6% for NU, 35.0% for the SU and 23.6% for the 
TU group, while 3-year CSS was 69.2%, 67.6% and 61.0%, 
and 3-year OS was 55.3%, 57.5% and 55.0%, respectively 
(Fig. 2). The presence of an urothelial recurrence did not 
confer increased risk of cancer-specific (p = 0.73) or overall 
mortality (p = 0.39) (Fig. 3). This was further confirmed in 
the multivariable model (p = 0.27 and p = 0.62 for CSS and 
OS, respectively).
Univariable analysis for overall mortality demonstrated 
prognostic association with age (p = 0.01), T stage (p < 0.04), 
N stage (p < 0.01), grade (p = 0.02), and lymphovascu-
lar invasion (p < 0.01). The same factors, except for age, 
were also prognostic indicators for cancer-specific mortality 
(Table 2). In the multivariate model evaluating the relation-
ship between urothelial recurrence and mortality, only age 
(p < 0.01) and N stage (p < 0.01) remained significantly 
associated with overall mortality, while T stage (p = 0.02) 
and N stage (p = 0.01) continued to be associated with 
cancer-specific mortality. 
Fig. 1. Distribution of recurrences sites between ureteral resection (segmental ureterectomy and total ureterectomy) and nephroureterectomy.
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Discussion 
Although NU with removal of bladder cuff remains the 
standard of care to treat ureteral upper tract urothelial car-
cinoma, recent evidence regarding the survival impact of 
renal preservation and the role of renal-dependent chemo-
therapy agents for urothelial cancer have restored interest in 
urothelial-sparing approaches to manage this disease. The 
endoscopic approach relies on the use of laser techniques 
to ablate and/or resect the tumour, which may compromise 
adequate pathologic evaluation, thus subjecting patients to 
higher instances of under-treatment.7-9 By comparison, seg-
mental or complete ureteral resection allows for full thick-
ness excision of the involved ureter and peri-ureteral tissue, 
as well as allows us to perform lymph node dissection to 
complete pathologic staging. In our 45 patients undergo-
ing SU or TU for upper tract urothelial carcinoma, all had 
adequate pathologic specimen for analysis, and pT3 dis-
ease was identified in 7 (15.5%) patients and positive lymph 
nodes in 3 (6.7%). 
Nephrectomy is associated with an average 25% reduc-
tion of global renal function; this diminished postoperative 
eGFR has been independently associated with cardiovascu-
lar death and decreased OS.4,10 Additionally, the potential 
candidacy of urothelial carcinoma patients for adjuvant che-
motherapy and/or clinical trials should be considered prior 
to surgical planning. According to several reports, an esti-
mated 88% to 93% of patients in the post-NU setting have 
an eGFR <60 and would be ineligible to receive cisplatin-
based therapy.5,11 Although increasing utilization of neoadju-
vant chemotherapy for upper tract urothelial carcinoma may 
partially obviate the importance of ureteral resection in this 
disease population, these findings retain oncologic impor-
tance for several reasons: (1) eligibility for clinical trials; (2) 
risk for the development  of  muscle-invasive  bladder  can-
cer  where  chemotherapy  is  well-established; and (3) lower 
efficacy of non-cisplatin based palliative chemotherapy.12-14
Segmental resections for upper tract urothelial carcino-
ma have traditionally been associated with high recurrence 
rates.15 Although this is concerning in this patient popula-
tion, this data were often confounded by publications that 
combined NU patients with and without complete ure-
terectomy and bladder cuff.16 These inadequately treated 
patients, many of whom would never have been ureteral 
resection candidates, were subjected to unfortunate “stump 
recurrences,” skewing the interpretation of results.17 When 
analyzing patients exclusively with SU, published series 
have shown much more encouraging outcomes.18,19 Colin 
and colleagues, in the largest published study, evaluated 
52 distal SU patients and 416 NU patients, demonstrating 
similar 5-year DSS (87.9% vs. 86.3%, p = 0.99).20 Jedres 
and colleagues performed a Surveillance, Epidemiology, and 
End Results (SEER)-database review of 569 SU and 1222 NU 
patients and described similar oncologic outcomes between 
groups (5-year DSS 86.6% vs. 82.2%, p = 0.05).21 Our 3-year 
DSS and OS for the ureterectomy group (SU and TU) was 
69.7% and 54.9% compared to 69.2% and 56.3% for the 
NU group (p = 0.78 and p = 0.80, respectively). 
Despite not reaching statistical significance, we found 
higher a incidence of recurrence in the segmental resection 
population, with a 3-year RFS of 33.7% in the ureterectomy 
group versus 48.7% in the NU group (p = 0.27). Differences 
are consistent with the presence of ipsilateral upper tract 
recurrences in the ureterectomy group that is completely 
negated in the nephroureterectomy arm. Recent publica-
tions have reported a 9% to 11% ipsilateral recurrence rate 
Fig. 2. A: Recurrence-free survival; B: cancer-specific survival; and C: overall survival curves according to type of resection.
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in patients undergoing segmental resection.13,20,21 Our series 
of patients (SU and TU) demonstrated an 11.1% ipsilateral 
upper tract recurrence rate, commensurate with prior lit-
erature (Fig. 1).
Estimating the impact of SU on oncologic outcomes is 
challenging due to the inability to determine whether recur-
rences are caused by disease persistence from incomplete 
local resection versus de novo disease in the affected urinary 
tract. Raman and colleagues13 demonstrated that over 60% 
of bladder recurrences after NU had different pathologic 
characteristics, favouring de novo disease as an explanation 
for these failures. These findings suggest that the increased 
surface of urothelium may harbor genetic alterations, pre-
disposing patients to urothelial recurrences. In our series 
the most common recurrence site was bladder (23.4% of 
patients), in which 73% of these recurrences were pT1 or 
less. Aside from distant metastases, the next most common 
recurrence site was the ipsilateral upper tract seen in 5 
(3.5%) cases. Among these patients, 3 were localized in the 
ipsilateral renal pelvis, away from the initial resection site. 
Again, these findings reinforce our hypothesis that de novo 
disease may be the primary contributor to disease relapse 
in this setting.
Do localized disease recurrences actually affect survival 
in patients with upper tract urothelial carcinoma? In our 
series we found no association between this type of recur-
rence and CSS (3-year CSS 72.2% vs. 65.3%, p = 0.73) or OS 
(3-year OS 65.6% vs. 50.9%, p = 0.34) (Fig. 3). Additionally, 
our findings were again supported using a multivariable 
model demonstrating that age and initial tumour stage (pT 
and pN) were the major predictors of survival, irrespective of 
the presence of urothelial recurrence. This data were again 
concordant with the current literature that fails to show clear 
differences in survival between segmental resection and 
nephroureterectomy for upper tract urothelial carcinoma. 
Despite similarities in DSS, patients experiencing ipsilat-
eral recurrence after local resection are prone to physical 
morbidity from a higher burden of treatment, as well as 
emotional stressors related to disease failure, which should 
be considered during preoperative planning at the time of 
initial diagnosis.
The limitations of our study include its retrospective 
nature and relatively small number of patients. Pathologic 
analysis and surgical technique, including the performance 
and technique of lymph node dissection, were not stan-
dardized and may have affected our results. As previously 
described, the technique for confection of ileal ureter during 
TU followed the same principles as described in a previous 
publication.6 Additionally, longer follow-up will be needed 
to better assess the oncologic legitimacy of ureteral resec-
tions for upper tract urothelial carcinoma. Due to the rarity 
of the disease, multi-institutional collaboration is imperative. 
Despite these limitations, our study represents one of the 
largest contemporary series evaluating the role of ureteral 
resections for both limited and extensive localized upper 
tract urothelial carcinoma.
Conclusion 
Ureteral resection for localized upper tract urothelial cancer 
offers preservation of renal function in a population where 
chronic kidney failure is highly prevalent. Even though local 
urothelial recurrences remain high, the impact of segmen-
tal resection on overall disease survival appears minimal. 
Although feasible, outcomes of total ureteral removal with 
ileal reconstruction remain preliminary and TU should cur-
Fig. 3. A: Cancer-specific survival; B: overall survival curves according to the presence of urothelial recurrence.
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rently be reserved as an alternative to segemental ureter-
ectomy or nephroureterectomy for patients with extensive 
ureteral disease and poor renal function.
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Table 2. Univariable and multivariable Cox proportional hazard models for CSS and RFS including the presence of urothelial 
recurrence
                                    Multivariable Cox proportional hazards
Variables Overall mortality Cancer specific mortality
Univariable Multivariable Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value HR (95% CI)
p 
value
HR (95% CI) p value
Age (cont.) 1.03 (1.01–1.06) 0.01 1.04 (1.02–1.07) <0.01 1.01 (0.98–1.04) 0.63 - -
Sex (male) 0.43 (0.50–1.34) 0.43 - - 0.81 (042–1.54) 0.52 - -
Race (Caucasian) 1.17 (0.50–2.70) 0.71 - - 0.97 (0.30–3.14) 0.95 - -
CCI (cont.) 1.16 (0.98–1.36) 0.08 - - 0.97 (0.75–1.24) 0.79 - -
T stage (T3 and T4) 2.73 (1.69–4.42) <0.01 1.34 (0.67-2.69) 0.41 5.05 (270–9.45) <0.01 2.88 (1.17–7.11) 0.02
N stage (N positive) 4.76 (2.73–8.30) <0.01 3.16 (1.47–6.79) <0.01 7.30 (3.75–14.21) <0.01 3.05 (1.23–7.57) 0.01
Grade (high grade) 2.11 (1.08–4.14) 0.02 1.23 (0.59–2.56) 0.58 2.58 (1.01–6.58) 0.04 1.30 (0.45–3.71) 0.60
LVI (presence) 3.78 (2.25–6.33) <0.01 1.87 (0.93–3.77) 0.08 4.93 (2.59–9.38) <0.01 1.31 (0.51–3.34) 0.56
CIS (presence) 1.02 (0.59–1.77) 0.93 - - 1.48 (0.77–2.86) 0.24 - -
Type of resection 
(SU and TU)
0.93 (0.56–1.56) 0.80 - - 1.10 (0.57–2.10) 0.78 - -
Urothelial rec. 
(presence)
0.78 (0.46–1.31) 0.34 1.15 (0.66–1.97) 0.62 0.89 (0.46–1.73) 0.74 1.48 (0.73–2.98) 0.27
CSS: cancer-specific survival; RFS: recurrence-free survival; HR: hazard ratio; CI: confidence interval; HR: hazard ratio; CCI: Charlson Comorbidity Index; LVI: lymphovascular invasion; CIS: 
carcinoma in situ; SU: segmental ureterectomy; TU: total ureterectomy; SU: segmental ureterectomy; NU: nephroureterectomy.
